A Phase 1 interventional study of LXI-15028 50mg and LXI-15028 100mg in Healthy, sponsored by Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-30.
Sponsored by Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
"This study is a single-center, randomized, double-blinded and placebo-controlled trial designed not only to assess pharmacokinetics, safety and tolerability of LXI-15028 but also to evaluate the pharmacokinetic characteristics of main metabolite M1 in vivo in 38 healthy adult Chinese subjects after receiving escalating single oral doses of 50 mg, 100 mg and 200 mg and multiple oral doses of 100 mg of LXI-15028.
This study includes 3 dose groups which are 50 mg (Group 1), 100 mg(Group 2) and 200 mg(Group 3) respectively. For 50 mg and 200 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo; 100 mg dose group plans to enroll 14 healthy subjects (investigational drug:placebo=10:4), half males and half females. Five subjects of each gender will receive LXI-15028, while 2 subjects of each gender will receive placebo. Intra-group randomization will be implemented in each dose group; each subject will receive either LXI-15028 or placebo.
This study includes 2 parts of single-dose and multiple-dose administration. The single-dose study will use gradually escalation dosing to evaluate the 3 doses of 50 mg, 100 mg and 200 mg. Within 4 days after each dose is administered, the investigators will assess the safety and tolerability data to decide whether to proceed with the next escalated single dose. Within 4 days of 200 mg single-dose administration, the investigators will assess the safety and tolerability data to decide whether to proceed with 100 mg multiple-dose study. Multiple-dose study will be investigated in 100 mg group only.
The study consists of screening period, treatment period and follow-up in each dose group. The treatment period in 50 mg and 200 mg dose groups include single-dose administration only. While the treatment period in 100 mg dose group includes both single-dose and multiple-dose administration. The subjects in 100 mg dose group will enter multiple-dose period following completing single-dose period.
In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state, or 100 mg LXI-15028 tablet or matching placebo 1 tablet, or 2 100 mg LXI-15028 tablets or 2 matching placebo tablets. Blood samples will be collected before administration (0h), and 15 min (0.25h), 30 min (0.5h), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after administration. In multiple-dose study, the subjects will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times. Blood samples of trough concentration will be collected before the 8th to 10th administration (0h) in multiple-dose study. And blood samples will be collected at 15 min (0.25h), 30 min (0.5h), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after the 10th administration.
The collected blood samples will be processed to obtain plasma. Liquid Chromatographic(LC) /Mass Spectra(MS)/Mass Spectra (MS) method will be used to determine plasma concentrations of LXI-15028 and its major metabolite M1 in order to evaluate the pharmacokinetic characteristics of LXI-15028 and its metabolite M1 after oral administration of LXI-15028 tablet.
The safety will be assessed by physical examination, vital signs, ECG, laboratory examinations and adverse events in subjects receiving LXI-15028 tablet.
"
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The subjects with presence of one of the following infectious diseases;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For 50 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
Drug: LXI-15028 50mg · Drug: Placebo
100 mg dose group plans to enroll 14 healthy subjects (investigational drug:placebo=10:4), half males and half females. Five subjects of each gender will receive LXI-15028, while 2 subjects of each gender will receive placebo. Intra-group randomization will be implemented in each dose group; each subject will receive either LXI-15028 or placebo.
Drug: LXI-15028 100mg · Drug: Placebo
200 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
Drug: LXI-15028 200mg · Drug: Placebo
In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
matching placebo tablets
Pharmacokinetic parameter: Cmax
The maximum plasma concentration (Cmax) after single dose LXI-15028
Time frame: 72 h after receiving single oral dose
Pharmacokinetic parameter: Tmax
The peak time (Tmax) after single dose LXI-15028
Time frame: 72 h after receiving single oral dose
Pharmacokinetic parameter: T1/2
The elimination half-life T1/2 after single dose LXI-15028
Time frame: 72 h after receiving single oral dose
Pharmacokinetic parameter: Kel
The eliminate rate constant after single dose LXI-15028
Time frame: 72 h after receiving single oral dose
Pharmacokinetic parameter:Mean Residence Time(MRT)
The mean residence time after single dose LXI-15028
Time frame: 72 h after receiving single oral dose
Pharmacokinetic parameter: Area Under plasma Concentration(AUC 0-24h)
The area under plasma concentration -time curve from 0 time ot 24 h after single dose LXI-15028
Time frame: 24h after receiving single oral dose
Pharmacokinetic parameter: AUC 0-last
The area under plasma concentration- time curve from 0 time to sampling time of the last measurable concentration after single dose LXI-15028
Time frame: 72h after receiving single oral dose
Pharmacokinetic parameter: AUC 0-inf
The area under plasma concentration-time curve from adminstration (0)to infinity after single dose LXI-15028
Time frame: 72h after receiving single oral dose
Pharmacokinetic parameter: Vd/F
The apparent volume of distribution after single dose LXI-15028
Time frame: 72h after receiving single oral dose
Pharmacokinetic parameter: Css min
The trough concentration at steady state(Css min) after multiple doses
Time frame: predose at day 8, 9, and 10, 72 h after receiving last multiple oral doses
Pharmacokinetic parameter: Css max
The peak concentration at steady state (Css max) after multiple doses
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter: Css av
The average concentration at steady state (Css, av)after multiple doses
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter: Tss max
The peak time after multiple doses
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter: Tss,1/2
The steady-state clearance half-time after multiple doses
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter: CLss/F
Total body clearance after multiple doses
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter: coefficient of fluctuation (DF)
coefficient of fluctuation after multiple doses
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter: Area Under plasma Concentration at steady state (AUC ss)
The area under plasma concentration-time curve at steady state after multiple doses
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter: Rac
The accumulation coefficient after multiple doses
Time frame: 72 h after receiving last multiple oral doses
Physical examination value of single dose
This measure is a composite. Evaluate safety and tolerability of single dose in Physical examination that should cover the head, eyes, ears, nose, throat, cardiovascular system, skin, musculoskeletal, respiratory system, digestive system, urinary system and nervous system and changes of each item from the baseline are summarized. The measurement results of each subject are summarized by different severity. All physical examination results during this trial will be listed in details.
Time frame: Baseline to Day 4 after receiving single oral dose
Vital signs value of single dose
The measure is a composite.Evaluate safety and tolerability of single dose in Vital signs value that including blood pressure (Systolic blood pressure/Diastolic blood pressure), pulse, body temperature,each vital sign examination values at each evaluation time point and their changes relative to the baseline will be summarized. All vital sign results should be listed. The listed vital signs are compared with normal ranges to determine whether is abnormal. The examination results that are divided into higher than normal range, normal and lower than normal range will be summarized by number of cases (n) and percentage (%). The results of abnormalities(\> or \< normal range) are listed.
Time frame: Up to 3weeks
12-lead ECG value of single dose
Evaluate safety and tolerability of single dose in 12-lead ECG value that including ventricular rate (beats/min), PR interval (ms), QRS (ms) , QT(ms),QTc (ms), the examination results of each ECG parameters and their changes from baseline will be summarized at each time point. Meanwhile, all 12-lead ECG examination results will be listed in details.
Time frame: Up to 3 weeks
Blood routine value of single dose
Evaluate safety and tolerability of single dose in blood routine value that including White blood cells (WBC), red blood cells (RBC), hemoglobin (Hb), hematocrit (Hct), platelet, neutrophils, lymphocytes, monocytes, eosinophils, basophils, absolute neutrophil counts (ANC);and list all the result.
Time frame: Baseline to Day 4 after receiving single oral dose
Urine routine value of single dose
Evaluate safety and tolerability of single dose in urine routine value that including specific gravity, pH, proteins, ketone,occult blood; and list all the result.
Time frame: Baseline to Day 4 after receiving single oral dose
Blood coagulation value of single dose
Evaluate safety and tolerability of single dose in blood coagulation value that including International normalized ratio (INR), activated partial thromboplastin time (aPTT), prothrombin time (PT); and list all the result.
Time frame: Baseline to Day 4 after receiving single oral dose
Blood biochemistry value of single dose
Evaluate safety and tolerability of single dose in blood biochemistry value that including Cholesterol, total proteins, albumin, total bilirubin, Conjugated bilirubin, creatinine, creatine kinase (CPK), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyltransferase (γ-GT), magnesium, sodium, potassium, chlorine, total calcium, inorganic phosphorus, lactate dehydrogenase (LDH), glucose, uric acid, triglyceride (TG); and list all the result.
Time frame: Baseline to Day 4 after receiving single oral dose
Adverse events of single dose
The adverse events are encoded using MedDRA 20.1. According to system organ classification (SOC) and preferred term (PT), all TEAE, investigational drug-related TEAE, Serious Adverse Event, investigational drug-related SAE, and TEAE causing premature withdrawal from this study will be separately summarized by different dose groups, including number of subjects experiencing Adverse Event, percentage and number of AE cases. The summary results are sorted according to the ranking number of cases of all subjects experiencing AE. All AE and SAE are listed by different dose groups.
Time frame: Up to 3 weeks
Physical examination value of multiple doses
The measure is a composite. Evaluate safety and tolerability of multiple doses in Physical examination that should cover the head, eyes, ears, nose, throat, cardiovascular system, skin, musculoskeletal, respiratory system, digestive system, urinary system and nervous system and changes of each item from the baseline are summarized. The measurement results of each subject are summarized by different severity. All physical examination results during this trial will be listed in details.
Time frame: Baseline to Day 21 after receiving the first dose
Vital signs value of multiple doses
The measure is a composite.Evaluate safety and tolerability of multiple doses in Vital signs value that including blood pressure(Systolic blood pressure/Diastolic blood pressure), pulse, body temperature.Each vital sign examination values at each evaluation time point and their changes relative to the baseline will be summarized. All vital sign results should be listed. The listed vital signs are compared with normal ranges to determine whether is abnormal. The examination results that are divided into higher than normal range, normal and lower than normal range will be summarized by number of cases (n) and percentage (%). The results of abnormalities(\> or \< normal range) are listed.
Time frame: Baseline to Day 21 after receiving the first dose
12-lead ECG value of multiple doses
Evaluate safety and tolerability of multiple doses in 12-lead ECG value that including ventricular rate (beats/min) ,PR interval (ms), QRS (ms) ,,QT(ms), QT interval (QTc )(ms). The examination results of each ECG parameters and their changes from baseline will be summarized at each time point. Meanwhile, all 12-lead ECG examination results will be listed in details.
Time frame: :Baseline to Day 21 after receiving the first dose
Blood routine value of multiple doses
Evaluate safety and tolerability of multiple doses in blood routine value that including White blood cells (WBC), red blood cells (RBC), hemoglobin (Hb), hematocrit (Hct), platelet, neutrophils, lymphocytes, monocytes, eosinophils, basophils, absolute neutrophil counts (ANC); and list all the result.
Time frame: Baseline to Day 21 after receiving the first dose
Urine routine value of multiple doses
Evaluate safety and tolerability of multiple doses in urine routine value that including specific gravity, potential of hydrogen (pH), proteins, ketone,occult blood; and list all the result.
Time frame: Baseline to Day 21 after receiving the first dose
Blood coagulation value of multiple doses
Evaluate safety and tolerability of multiple doses in blood coagulation value that including International normalized ratio (INR), activated partial thromboplastin time (aPTT), prothrombin time (PT);
Time frame: Baseline to Day 21 after receiving the first dose
Blood biochemistry value of multiple doses
Evaluate safety and tolerability of multiple doses in blood biochemistry value that including Cholesterol, total proteins, albumin, total bilirubin, Conjugated bilirubin, creatinine, creatine kinase (CPK), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyltransferase (γ-GT), magnesium, sodium, potassium, chlorine, total calcium, inorganic phosphorus, lactate dehydrogenase (LDH), glucose, uric acid, triglyceride (TG); and list all the result.
Time frame: Baseline to Day 21 after receiving the first dose
Adverse events of multiple doses
The adverse events are encoded using MedDRA 20.1. According to system organ classification (SOC) and preferred term (PT), all treatment-emergent adverse event (TEAE), investigational drug-related TEAE, serious adverse event (SAE), investigational drug-related SAE, and TEAE causing premature withdrawal from this study will be separately summarized by different dose groups, including number of subjects experiencing AE, percentage and number of adverse event (AE) cases. The summary results are sorted according to the ranking number of cases of all subjects experiencing AE. All AE and SAE are listed by different dose groups.
Time frame: Up to 6 weeks
Pharmacokinetic parameter of major metabolite(M1): Cmax
Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: peak concentration Cmax
Time frame: 72 h after receiving single oral doses
Pharmacokinetic parameter of major metabolite(M1): Tmax
Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: peak time Tmax
Time frame: 72 h after receiving single oral doses
Pharmacokinetic parameter of major metabolite(M1): T1/2
Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: elimination half-life T1/2
Time frame: 72 h after receiving single oral doses
Pharmacokinetic parameter of major metabolite(M1): Kel
Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: eliminate rate constant
Time frame: 72 h after receiving single oral dose
Pharmacokinetic parameter of major metabolite(M1): MRT
Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: mean residence time
Time frame: 72 h after receiving single oral dose
Pharmacokinetic parameter of major metabolite(M1): AUC 0-24h
Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: area under plasma concentration-time curve from 0 time to 24 hours
Time frame: 24 h after receiving single oral dose
Pharmacokinetic parameter of major metabolite(M1): AUC 0-last
Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: area under plasma concentration-time curve from 0 time to the last measurable concentration
Time frame: 72 h after receiving single oral dose
Pharmacokinetic parameter of major metabolite(M1): AUC 0-inf
Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: area under plasma concentration-time curve from 0 time to infinity
Time frame: 72h after receiving single oral dose
Pharmacokinetic parameter of major metabolite(M1): CL/F
Major metabolite (M1) of LXI-15028 Plasma PK parameters of single dose:apparent total clearance
Time frame: 72h after receiving single oral dose
Pharmacokinetic parameter of major metabolite(M1): Vd/F
Major metabolite (M1) of LXI-15028 Plasma PK parameters of single dose: apparent volume of distribution
Time frame: 72h after receiving single oral dose
Pharmacokinetic parameter of major metabolite(M1): Css, min
Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: trough concentration at steady state
Time frame: :predose at day 8, 9, and 10, 72 h after receiving last multiple oral doses
Pharmacokinetic parameter of major metabolite(M1): Css, max
Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses:peak concentration at steady state
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter of major metabolite(M1): Css, av
Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: average concentration at steady state
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter of major metabolite(M1): Tss, max
Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: peak time
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter of major metabolite(M1): Vss/F
Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses:apparent volume of distribution at steady state
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter of major metabolite(M1): tss,1/2
Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses:steady-state clearance half-life
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter of major metabolite(M1): CLss/F
Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses:total body clearance
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter of major metabolite(M1): DF
Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses: coefficient of fluctuation
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter of major metabolite(M1): AUCss
Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses: area under plasma concentration-time curve at steady state
Time frame: 72 h after receiving last multiple oral doses
Pharmacokinetic parameter of major metabolite(M1): Rac
Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: accumulation coefficient
Time frame: 72 h after receiving last multiple oral doses
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2018 to primary completion in Apr 2018, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprazan
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.